Corpus Intelligence IC Memo — CCH - SAUK CENTRE 2026-04-26 13:28 UTC
IC Memo — CCH - SAUK CENTRE
Investment Committee Memorandum | MN | 14 beds | Grade C | EBITDA uplift $3.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CCH - SAUK CENTRE

CCN 241368 | STEARNS, MN | 14 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CCH - SAUK CENTRE is a 14-bed suburban community hospital in STEARNS, MN with $41.1M in net patient revenue and a 2.8% operating margin. The hospital serves a payer mix of 30.8% Medicare, 1.8% Medicaid, and 67.4% commercial.

Thesis: Turnaround. Our ML models identify $3.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.8% to 10.2% (+736bps).

Net Revenue HCRIS$41.1M
Current EBITDA COMPUTED$1.2M
Operating Margin COMPUTED2.8%
Occupancy HCRIS40.9%
Revenue / Bed COMPUTED$2.9M
Net-to-Gross HCRIS61.7%
Distress Probability ML50.5%

2. Market Context & Competitive Position

141
MN Hospitals
-3.6%
State Median Margin
85
Comparable Hospitals

MN has 141 Medicare-certified hospitals with a median operating margin of -3.6%. The target's margin of 2.8% places it above the state median. Among 85 size-comparable peers (7-28 beds), the median margin is -3.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (7-28), prioritizing same-state peers. 85 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CCH - SAUK CENTRE (Target)MN14$41.1M2.8%
CUYUNA REGIONAL MEDICAL CENTERMN25$180.8M-4.0%
MAYO CLINIC HEALTH SYSTEM - REMN27$149.3M1.8%
NEW ULM MEDICAL CENTERMN24$128.6M4.2%
LAKEWOOD HEALTH SYSTEMMN25$124.7M0.2%
AVERA MARSHALL REGIONAL MEDICAMN25$115.2M-17.0%
WELIA HEALTHMN25$106.7M1.1%
CCH-MONTICELLOMN25$97.7M9.2%
RIVERWOOD HEALTHCARE CENTERMN25$85.5M-2.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$864K+210bp18mo
Cost to Collect4.5%2.5%$823K+200bp12mo
Denial Rate Reduction12.0%6.5%$815K+198bp12mo
A/R Days Reduction5200.0%3800.0%$501K+122bp9mo
Clean Claim Rate88.0%96.0%$26K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$864K
Cost to Collect
$823K
Denial Rate Reduction
$815K
A/R Days Reduction
$501K
Clean Claim Rate
$26K
Total EBITDA Uplift$3.0M
Current EBITDA$1.2M
+ RCM Uplift+$3.0M
Pro Forma EBITDA$4.2M
Current Margin2.8%
Pro Forma Margin10.2%
WC Released (1x)$1.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.8M$38.0M21.24x84.3%
Base (11x exit)10.0x11.0x$1.8M$42.3M23.69x88.3%
Bull Case9.0x11.0x$1.6M$52.9M32.89x101.1%
Bull (12x exit)9.0x12.0x$1.6M$58.2M36.18x105.0%
Bear Case11.0x10.0x$2.0M$22.2M11.31x62.4%
Bear (11x exit)11.0x11.0x$2.0M$25.1M12.76x66.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighElevated distress probabilityModel estimates 50.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 85 hospitals with 7-28 beds
  • Same-state prioritization (n=89)
  • Comp margins: P25=-13.2% / P50=-3.0% / P75=3.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.